US4911929A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Blood substitute comprising liposome-encapsulated hemoglobin
Assignee: United States Department of the Navy
•
Filing: 1988-05-09
•
Granted: 1990-03-27
•
Expires: 2008-05-09
Abstract
Abstract Sterile liposome-encapsulated hemoglobin having an oxygen carrying capacity of 20 vol/%, a half life of 15-20 hours as measured in mice, with the liposome made from chloroform, HSPC, cholesterol, negatively charged DMPG and alpha-tocopherol.
Inventors
- 👤 Martha C. Farmer
- 👤 Richard L. Beissinger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 22:38
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/41; A61K38/42; A61K9/00; A61K9/10; A61K9/127; A61K9/1277; Y; Y10; Y10S; Y10S436/00; Y10S436/829; Y10T; Y10T428/00; Y10T428/29; Y10T428/2982; Y10T428/2984
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
92 words
A blood substitute having a T 1/2 of at least 15 hours as measured in mice comprising a fluid medium; and vesicles of a well-defined spherical structure and diameters between 0.15-0.4 microns, said vesicles comprising biologically active hemoglobin and a lipid membrane encapsulating said hemoglobin, said membrane being of at least one lipid bilayer consisting essentially of: about 30-50 mole percent of cholesterol, about 40-60 mole percent of a saturated phosphatidylcholine with an acyl chain in excess of 14 carbons and about 2 to 10 mole percent of a negatively charged lipid.
Claim 2
Dependent Claim
92 words
A blood substitute having a T 1/2 of at least 15 hours as measured in mice comprising a fluid medium; and vesicles of a well-defined spherical structure and diameters between 0.15-0.4 microns, said vesicles comprising biologically active hemoglobin and a lipid membrane encapsulating said hemoglobin, said membrane being of at least one lipid bilayer consisting essentially of: about 30-50 mole percent of cholesterol, about 40-60 mole percent of a saturated phosphatidylcholine with an acyl chain in excess of 14 carbons and about 2 to 10 mole percent of a negatively charged lipid.
Claim 3
Dependent Claim
18 words
A blood substitute as described in claim 1 which contains 0 to 10 mole percent lipid soluble antioxidant.
Claim 4
Dependent Claim
22 words
A blood substitute as described in claim 2 which includes 0 to 10 percent of alpha tocopherol as the lipid soluble antioxidant.
Claim 5
Dependent Claim
16 words
A blood substitute as described in claim 2 which contains sialic acid derivatives of the phosphatidylcoline.
Claim 6
Dependent Claim
52 words
A blood substitute as described in claim 2 wherein the phosphatidylcholine is selected from the group consisting of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylcholine and sialic acid derivatives of said phosphatidylcholines and the negatively charged lipid is chosen from the group consisting of phosphatidic acid, dicetyl phosphate and dimyristoyl, dipalmitoyl, or distearoyl-phosphatidyl glycerol.
Claim 7
Dependent Claim
17 words
A blood substitute as described in claim 5 wherein the negatively charged lipid is dimyristoyl phosphatidyl glycerol.
Claim 8
Dependent Claim
58 words
A blood substitute comprising a fluid medium; and vesicles of a well-defined spherical structure and diameters of between 0.15-0.4 microns, said vesicles comprising stroma-free biologically active hemoglobin and a lipid bilayer encapsulating said hemoglobin, said bilayer consisting essentially of: hydrogenated soy phosphatidylcholine or distearoyl phosphatidylcholine cholesterol, dimyristoyl phosphatidyl glycerol, and alpha tocopherol in a molar ratio of 5:4:1:0.2.
Claim 9
Dependent Claim
58 words
A blood substitute comprising a fluid medium; and vesicles of a well-defined spherical structure and diameters of between 0.15-0.4 microns, said vesicles comprising stroma-free biologically active hemoglobin and a lipid bilayer encapsulating said hemoglobin, said bilayer consisting essentially of: hydrogenated soy phosphatidylcholine or distearoyl phosphatidylcholine cholesterol, dimyristoyl phosphatidyl glycerol, and alpha tocopherol in a molar ratio of 5:4:1:0.2.
References Cited (Backward Citations)
US4016100A
Cited
US4133874A
Cited
US4448765A
Cited
WO1983000089A1
Cited
US4532130A
Cited
US4483873A
Cited
US4425334A
Cited
US4649151A
Cited
US4501728A
Cited
US4515736A
Cited
US4675310A
Cited
US4776991A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-26 | 1993-09-25 | 1994-03-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-26 | 1997-09-25 | 1998-03-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-26 | 2001-09-25 | 2002-03-27 | $7700.00 | Window Closed / Lapsed |